The nitric oxide-independent soluble guanylate cyclase activator ataciguat continued to show promise for slowing the ...

The phase II data are promising for patients who are managed with watchful waiting before being offered an intervention.

Ataciguat, a new drug being studied for aortic valve stenosis, shows promise in slowing disease progression and reducing the ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.

Safety of use during pregnancy or breastfeeding is uncertain. These drugs also act to increase intestinal fluid and intestinal movement by targeting receptors called guanylate cyclase-C (GC-C) ...

This process is similar to the PDE5 inhibitors, so these two medicine classes aren't taken together. Adempas (riociguat) is the only drug in its class of soluble guanylate cyclase (sGC) stimulators.

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers are exploring the use of a new drug called ataciguat to manage ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.

Expert Rev Clin Pharmacol. 2012;5(3):319-336. Finally, a recent study suggested that although prasugrel significantly reduces thrombotic events in patients with ACS undergoing PCI because of its ...